Your browser is no longer supported. Please, upgrade your browser.
Altimmune, Inc.
Index- P/E- EPS (ttm)-2.02 Insider Own1.10% Shs Outstand36.37M Perf Week-8.29%
Market Cap480.37M Forward P/E18.96 EPS next Y0.70 Insider Trans-9.20% Shs Float30.93M Perf Month1.14%
Income-49.00M PEG- EPS next Q-0.47 Inst Own61.60% Short Float15.66% Perf Quarter-27.72%
Sales8.20M P/S58.58 EPS this Y-19.70% Inst Trans11.47% Short Ratio3.59 Perf Half Y6.08%
Book/sh6.21 P/B2.14 EPS next Y134.30% ROA-30.90% Target Price- Perf Year325.32%
Cash/sh5.96 P/C2.22 EPS next 5Y- ROE-35.90% 52W Range3.03 - 35.10 Perf YTD17.64%
Dividend- P/FCF- EPS past 5Y34.70% ROI-21.90% 52W High-62.19% Beta1.64
Dividend %- Quick Ratio19.20 Sales past 5Y-5.10% Gross Margin- 52W Low337.95% ATR0.92
Employees43 Current Ratio19.20 Sales Q/Q283.30% Oper. Margin- RSI (14)46.95 Volatility7.55% 6.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.30% Profit Margin- Rel Volume0.49 Prev Close12.93
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume1.35M Price13.27
Recom1.70 SMA201.59% SMA50-6.41% SMA200-12.91% Volume655,984 Change2.63%
Feb-11-21Initiated Guggenheim Buy $36
Dec-14-20Initiated Jefferies Buy $25
Nov-12-20Reiterated B. Riley Securities Buy $31 → $28
Sep-25-20Initiated B. Riley FBR Buy $31
Aug-14-20Initiated Evercore ISI Outperform
Jul-31-20Initiated Piper Sandler Overweight $80
Jul-28-20Initiated JMP Securities Mkt Outperform $50
Feb-24-20Resumed ROTH Capital Buy $13
Jul-19-19Initiated ROTH Capital Buy $8.30
Oct-09-17Initiated Piper Jaffray Overweight $6
May-05-21 03:00PM  
Apr-29-21 07:00AM  
Apr-03-21 03:07AM  
Apr-01-21 07:00AM  
Mar-25-21 11:46AM  
Mar-22-21 07:00AM  
Mar-15-21 07:00AM  
Mar-14-21 05:55AM  
Mar-12-21 01:00AM  
Mar-09-21 09:40AM  
Mar-08-21 04:01PM  
Feb-25-21 11:15PM  
Feb-22-21 04:30PM  
Feb-18-21 10:24AM  
Feb-17-21 07:02AM  
Feb-01-21 10:30AM  
Jan-14-21 11:15PM  
Jan-11-21 11:23PM  
Jan-06-21 11:15PM  
Jan-04-21 09:46PM  
Dec-30-20 08:00AM  
Dec-23-20 04:01PM  
Dec-16-20 03:51PM  
Dec-11-20 07:00AM  
Dec-08-20 08:00AM  
Nov-25-20 07:00AM  
Nov-16-20 07:00AM  
Nov-13-20 05:23AM  
Nov-10-20 01:00AM  
Nov-09-20 04:05PM  
Nov-03-20 08:00AM  
Oct-30-20 02:40PM  
Oct-26-20 06:22AM  
Oct-15-20 07:00AM  
Oct-13-20 04:56AM  
Oct-12-20 07:01AM  
Sep-30-20 07:00AM  
Sep-28-20 04:01PM  
Sep-01-20 07:00AM  
Aug-27-20 08:17AM  
Aug-26-20 07:00AM  
Aug-25-20 07:00AM  
Aug-11-20 04:05PM  
Aug-07-20 07:00AM  
Aug-05-20 07:00AM  
Jul-22-20 07:30AM  
Jul-16-20 04:01PM  
Jul-13-20 09:40PM  
Jul-09-20 11:30AM  
Jul-08-20 08:04AM  
Jul-02-20 07:30PM  
Jun-30-20 07:00AM  
Jun-29-20 07:00AM  
Jun-22-20 07:00AM  
Jun-21-20 07:00AM  
Jun-17-20 08:45AM  
Jun-10-20 09:15AM  
Jun-09-20 09:15AM  
Jun-01-20 07:00AM  
May-28-20 11:34AM  
May-15-20 08:58AM  
May-13-20 05:18PM  
May-12-20 07:00AM  
May-09-20 08:11AM  
May-08-20 07:00AM  
May-06-20 02:50PM  
Apr-20-20 09:01AM  
Apr-13-20 08:58AM  
Apr-08-20 09:15AM  
Apr-02-20 02:51PM  
Mar-30-20 07:00AM  
Mar-27-20 07:15AM  
Mar-25-20 04:30PM  
Feb-28-20 07:00AM  
Feb-19-20 04:30PM  
Feb-04-20 07:00AM  
Jan-31-20 04:58PM  
Jan-23-20 07:00AM  
Jan-07-20 08:43AM  
Dec-23-19 03:59PM  
Nov-21-19 08:00AM  
Nov-13-19 04:15PM  
Nov-11-19 05:43AM  
Nov-06-19 07:00AM  
Nov-01-19 02:41PM  
Oct-10-19 07:00AM  
Sep-09-19 07:00AM  
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hodges PhilipDirectorMar 01Sale16.086,00096,4808,731Mar 01 07:00 PM
Schafer KlausDirectorDec 10Buy11.992,00023,9808,900Dec 11 07:00 PM
Hodges PhilipDirectorDec 01Sale13.541,22716,6140Dec 02 07:05 PM
GILL JOHNDirectorNov 30Sale11.928,425100,42611,199Dec 02 07:05 PM
Hodges PhilipDirectorNov 30Sale12.002,50030,00014,731Dec 02 07:05 PM
Drutz DavidDirectorNov 13Option Exercise2.406014417,603Nov 17 07:00 PM
Harris Matthew ScottDirectorNov 12Sale10.024,01540,2304,069Nov 13 06:00 PM
Pisano WayneDirectorNov 12Sale9.9010,352102,4858,498Nov 13 06:00 PM
Schafer KlausDirectorNov 12Sale9.9110,150100,5866,900Nov 13 06:00 PM
Hodges PhilipDirectorSep 24Option Exercise0.0016,850036,306Oct 16 07:00 PM
Pisano WayneDirectorSep 24Option Exercise0.0016,850018,850Oct 16 07:00 PM
GILL JOHNDirectorSep 24Option Exercise0.0016,850019,624Oct 16 07:00 PM
SAYARE MITCHELDirectorSep 24Option Exercise0.0025,275026,363Oct 16 07:00 PM
Schafer KlausDirectorSep 24Option Exercise0.0016,850017,050Oct 16 07:00 PM
Drutz DavidDirectorSep 24Option Exercise0.0016,850017,543Oct 16 07:00 PM
Venrock Healthcare Capital Par10% OwnerJun 15Buy7.541,500,00011,310,0004,500,000Jun 15 03:23 PM
Venrock Healthcare Capital Par10% OwnerMay 28Buy8.72201,4741,757,0903,000,000May 28 06:34 PM
Venrock Healthcare Capital Par10% OwnerMay 27Buy7.71402,1623,098,7612,798,526May 28 06:34 PM
Venrock Healthcare Capital Par10% OwnerMay 26Buy9.34700,0006,539,6422,396,364May 28 06:34 PM
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 15Sale4.6530,622142,3921,687,250May 18 04:45 PM
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 14Sale4.81169,378814,7081,717,872May 18 04:45 PM